Press Releases

SCHAUMBURG, Ill.--(BUSINESS WIRE)-- Sparton Corporation (NYSE:SPA) today announced results for the first quarter of fiscal year 2019 ended September 30, 2018. Fourth Quarter Financial Results and Highlights Joseph J. Hartnett, Interim President & CEO, commented, "We are pleased to report that we have started the fiscal year off with a strong operating performance, supported

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 27th Annual Credit

LOS ANGELES--(BUSINESS WIRE)-- HyreCar Inc. (NASDAQ: HYRE), the car sharing marketplace for ride sharing, today reported financial results and provided a corporate update for the third quarter ended September 30, 2018. Financial Summary:    

DUBLIN--(BUSINESS WIRE)-- The "Europe Asthma Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. This latest research provides comprehensive insights into Asthma pipeline, epidemiology, market valuations, product sales, market forecast,

DUBLIN--(BUSINESS WIRE)-- The "Europe Crohn's Disease Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. Europe Crohn's Disease Market and Competitive Landscape - 2018, provides comprehensive insights into Crohn's Disease pipeline, epidemiology,

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced financial results for the third quarter ended September 30, 2018 and provided updates on its clinical and preclinical programs. “This was another productive quarter for Arcus as we began dosing patients with our

DUBLIN--(BUSINESS WIRE)-- The "Europe Ulcerative Colitis Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. Europe Ulcerative Colitis Market and Competitive Landscape - 2018, provides comprehensive insights into Ulcerative Colitis pipeline, epi

DUBLIN--(BUSINESS WIRE)-- The "Europe Nonalcoholic Steatohepatitis Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. Europe Nonalcoholic Steatohepatitis Market and Competitive Landscape - 2018, provides comprehensive insights into Nonalcoholic

DUBLIN--(BUSINESS WIRE)-- The "Europe Hypogonadism Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. This latest research provides comprehensive insights into Hypogonadism pipeline, epidemiology, market valuations, product sales, market forec

DUBLIN--(BUSINESS WIRE)-- The "Europe Friedreich's Ataxia Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. This latest research provides comprehensive insights into Friedreich's Ataxia pipeline, epidemiology, market valuations, product sales

DUBLIN--(BUSINESS WIRE)-- The "Europe Insomnia Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. Europe Insomnia Market and Competitive Landscape - 2018, provides comprehensive insights into Insomnia pipeline, epidemiology, market valuations, pr

DUBLIN--(BUSINESS WIRE)-- The "Europe Esophageal Cancer Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. This latest research provides comprehensive insights into Esophageal Cancer pipeline, epidemiology, market valuations, product sales, ma

BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2018. As of September 30, 2018, cash, cash equivalents and investments totaled $255.2 million. Aimmune also announced that the safety profile of AR101

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV) today provided a business update and reported financial results for the quarter ended September 30, 2018. Richard Toselli, M.D., President and Chief Executive Officer of InVivo, commented, “In the third quarter, we continued to focus efforts on and advance toward our top priority of initiating patient enrollmen

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the third quarter 2018. Recent Highlights Total revenue of $5.4 milli